Poxviral oncolytic vectors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9180150
SERIAL NO

12743412

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • TRANSGENE S.A.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Erbs, Philippe Dagneux, FR 21 66
Foloppe, Johann Strasbourg, FR 6 25

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 10, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00